OncoMatch/Clinical Trials/NCT06288360
Neoadjuvant Immunochemotherapy in PD-L1-negative LACC
Is NCT06288360 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Camrelizumab and Paclitaxel-albumin for cervical cancer.
Treatment: Camrelizumab · Paclitaxel-albumin · Cisplatin — This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Biomarker criteria
Required: PD-L1 (CD274) negative expression (combined positive score < 1)
Disease stage
Required: Stage IIB, IIIC1R
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or antibodies against immune co-stimulators (e.g., antibodies against ICOS, CD40, CD137, GITR, OX40 targets, etc.), or any other therapy targeting a tumor's immune mechanism of action
Lab requirements
Blood counts
wbc≥3.5*10^9/l, neu≥1.5*10^9/l, platelet≥100×10^9 /l
Kidney function
serum creatinine and blood urea nitrogen ≤the upper limit of normal value
Liver function
ast and alt ≤1.5 times normal upper limit; total bilirubin ≤1.5 times the upper limit of normal value
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify